57 related articles for article (PubMed ID: 38581254)
1. Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening: The STHLM3-MRI Randomized Clinical Trial.
Björnebo L; Discacciati A; Falagario U; Vigneswaran HT; Jäderling F; Grönberg H; Eklund M; Nordström T; Lantz A
JAMA Netw Open; 2024 Apr; 7(4):e247131. PubMed ID: 38648061
[TBL] [Abstract][Full Text] [Related]
2. Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer.
Buzzoni C; Auvinen A; Roobol MJ; Carlsson S; Moss SM; Puliti D; de Koning HJ; Bangma CH; Denis LJ; Kwiatkowski M; Lujan M; Nelen V; Paez A; Randazzo M; Rebillard X; Tammela TL; Villers A; Hugosson J; Schröder FH; Zappa M
Eur Urol; 2015 Nov; 68(5):885-90. PubMed ID: 25791513
[TBL] [Abstract][Full Text] [Related]
3. Unscreened older men diagnosed with prostate cancer are at increased risk of aggressive disease.
Tosoian JJ; Alam R; Gergis C; Narang A; Radwan N; Robertson S; McNutt T; Ross AE; Song DY; DeWeese TL; Tran PT; Walsh PC
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):193-196. PubMed ID: 28045113
[TBL] [Abstract][Full Text] [Related]
4. Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer.
Tosoian JJ; Zhang Y; Xiao L; Xie C; Samora NL; Niknafs YS; Chopra Z; Siddiqui J; Zheng H; Herron G; Vaishampayan N; Robinson HS; Arivoli K; Trock BJ; Ross AE; Morgan TM; Palapattu GS; Salami SS; Kunju LP; Tomlins SA; Sokoll LJ; Chan DW; Srivastava S; Feng Z; Sanda MG; Zheng Y; Wei JT; Chinnaiyan AM;
JAMA Oncol; 2024 Apr; ():. PubMed ID: 38635241
[TBL] [Abstract][Full Text] [Related]
5. [Prostate cancer screening-current overview].
De Vrieze M; Hübner A; Al-Monajjed R; Albers P; Radtke JP; Schimmöller L; Boschheidgen M
Radiologie (Heidelb); 2024 Jun; 64(6):479-487. PubMed ID: 38743100
[TBL] [Abstract][Full Text] [Related]
6. [Prostate cancer - diagnostics and screening].
Arnsrud Godtman R; Bratt O; Nordström T; Wallström J; Hugosson J
Lakartidningen; 2024 Apr; 121():. PubMed ID: 38647107
[TBL] [Abstract][Full Text] [Related]
7. Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening.
Auvinen A; Moss SM; Tammela TL; Taari K; Roobol MJ; Schröder FH; Bangma CH; Carlsson S; Aus G; Zappa M; Puliti D; Denis LJ; Nelen V; Kwiatkowski M; Randazzo M; Paez A; Lujan M; Hugosson J
Clin Cancer Res; 2016 Jan; 22(1):243-9. PubMed ID: 26289069
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer.
Newcomb LF; Schenk JM; Zheng Y; Liu M; Zhu K; Brooks JD; Carroll PR; Dash A; de la Calle CM; Ellis WJ; Filson CP; Gleave ME; Liss MA; Martin F; McKenney JK; Morgan TM; Tretiakova MS; Wagner AA; Nelson PS; Lin DW
JAMA; 2024 May; ():. PubMed ID: 38814624
[TBL] [Abstract][Full Text] [Related]
9. Cancer Stage Compared With Mortality as End Points in Randomized Clinical Trials of Cancer Screening: A Systematic Review and Meta-Analysis.
Feng X; Zahed H; Onwuka J; Callister MEJ; Johansson M; Etzioni R; Robbins HA
JAMA; 2024 Apr; ():. PubMed ID: 38583868
[TBL] [Abstract][Full Text] [Related]
10. Correction to: High-grade prostate cancer demonstrates preferential growth in the cranio-caudal axis and provides discrimination of disease grade in an MRI parametric model.
Br J Radiol; 2024 May; 97(1158):1202. PubMed ID: 38685713
[No Abstract] [Full Text] [Related]
11. Reply to "Prostate Cancer Screening and Prostate MRI: Hypotheses Founded on Uncertain Evidence".
de Oliveira Correia ET; Purysko AS; Paranhos BM; Shoag JE; Padhani AR; Bittencourt LK
AJR Am J Roentgenol; 2024 Mar; ():1. PubMed ID: 38506544
[No Abstract] [Full Text] [Related]
12. Prostate Cancer Screening and Prostate MRI: Hypotheses Founded on Uncertain Evidence.
Takahashi T
AJR Am J Roentgenol; 2024 Mar; ():1. PubMed ID: 38506539
[No Abstract] [Full Text] [Related]
13. Population-based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study.
Rannikko A; Leht M; Mirtti T; Kenttämies A; Tolonen T; Rinta-Kiikka I; Kilpeläinen TP; Natunen K; Lilja H; Lehtimäki T; Raitanen J; Kujala P; Ronkainen J; Matikainen M; Petas A; Taari K; Tammela T; Auvinen A
BJU Int; 2022 Aug; 130(2):193-199. PubMed ID: 34958531
[TBL] [Abstract][Full Text] [Related]
14. Repeated Prostate Cancer Screening Using Prostate-Specific Antigen Testing and Magnetic Resonance Imaging: A Secondary Analysis of the STHLM3-MRI Randomized Clinical Trial.
Nordström T; Annerstedt M; Glaessgen A; Carlsson S; Clements M; Abbadi A; Grönberg H; Jäderling F; Eklund M; Discacciati A
JAMA Netw Open; 2024 Feb; 7(2):e2354577. PubMed ID: 38324313
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
16. Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial.
Auvinen A; Tammela TLJ; Mirtti T; Lilja H; Tolonen T; Kenttämies A; Rinta-Kiikka I; Lehtimäki T; Natunen K; Nevalainen J; Raitanen J; Ronkainen J; van der Kwast T; Riikonen J; Pétas A; Matikainen M; Taari K; Kilpeläinen T; Rannikko AS;
JAMA; 2024 May; 331(17):1452-1459. PubMed ID: 38581254
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
